We use cookies to improve your experience. By your continued use of this site you accept such use.
World Health Organization (WHO)
Source: World Health Organization (WHO) |

The Access to COVID-19 Tools (ACT) Accelerator partnership welcomes commitment of 870 million vaccine doses and calls for more investment in all tools to end the pandemic

870 million vaccine doses for low and low-middle income countries over the next year

G7 leaders donate 870 million vaccine doses for low and low-middle income countries over the next year, vital for reducing virus transmission; G7 leaders emphasize the importance of all ACT-Accelerator tools to exit the pandemic; ACT-Accelerator’s funding gap remains significant with an urgent need for funding of tests, treatments and health…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine, 7 April 2021

Events under assessment are very rare, with low numbers reported among the almost 200 million individuals who have received the AstraZeneca COVID-19 vaccine

The COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) has reviewed reports of rare cases of blood clots with low platelets following vaccination with the AstraZeneca COVID-19 vaccine (including Covishield) since their onset a few weeks ago. At its most recent meeting on 7 April, 2021,…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Tunisia receives first batch of COVID-19 vaccines through COVAX Facility

The COVAX Initiative also provided the Ministry of Health with a set of 506,400 syringes and 1,100 safety boxes

Tunisia received today the first batch of 93,600 doses of Pfizer COVID-19 vaccines through the COVAX Facility. This delivery is part of a first wave of arrivals that will continue during the year, with the goal of vaccinating 20% ​​of the population in Tunisia. “This shipment represents an important step…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus - Ghana: COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout

Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via the COVAX Facility

COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week; Final first round of allocations for doses of AstraZeneca/Oxford and Pfizer-BioNTech vaccines, to the majority of countries and economies participating in the COVAX Facility,…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus - The Oxford/AstraZeneca COVID-19 vaccine: what you need to know

Vaccination is recommended for persons with comorbidities that have been identified as increasing the risk of severe COVID-19

The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine (AZD1222).  Here’s a brief summary; you may access the guidance document here.  Who should be vaccinated first? While vaccine supplies are limited, it is recommended that priority be given…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus: COVAX announces new agreement, plans for first deliveries

COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021

COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements; additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus: Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries

The Global Fund commits an initial US$50 million to enable countries to purchase the new tests

A full access package includes WHO policy guidance on the use of antigen-based rapid diagnostic tests, manufacturer volume guarantees for low and middle-income countries, catalytic funding to assist governments to deploy the tests and an initial US$50 million procurement fund; several rapid, point-of-care antigen tests are being assessed by WHO for…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus: Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX facility

156 economies, representing roughly 64% of the global population in total, are now either committed to or eligible for the COVAX Facility

64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days; these self-financing economies, which include 29 from ‘Team Europe’ participating as part of an agreement with the European Commission, join 92 lower income economies eligible for financial support…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus: WHO Guidance on the use of corticosteroids in patients with COVID-19

Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost

WHO has published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients with non-severe COVID-19 as the treatment. Corticosteroids…

World Health Organization (WHO)
Source: World Health Organization (WHO) |

Coronavirus - Africa: 172 Countries & Multiple Candidate Vaccines engaged in COVID-19 Vaccine Global Access Facility

Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries

Nine CEPI-supported candidate vaccines are part of the COVAX initiative, with a further nine candidates under evaluation, and procurement conversations on-going with additional producers not currently receiving research and development (R&D) funding through COVAX – giving COVAX the largest and most diverse COVID-19 vaccine portfolio in the world; 80 potentially…